Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
This article was originally published in PharmAsia News
SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
You may also be interested in...
To help cope with the rising number of patients with A/H1N1, Korea handed over some of its government stockpile of Tamiflu supplies to Roche.
Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.
MFDS rejects Korea Centers for Disease Control and Prevention bid to retain expiring Tamiflu stockpile. South Korea would need to replace expiring supplies to maintain same levels of stockpile.